Migraines Are Not Just Headaches with Hubert Martens

<p>In this episode of the Crux of Neuro, Liz Moyles is joined by Hubert Martens, physicist-turned-entrepreneur, co-founder of Sapiens Steering Brain Stimulation (acquired by Medtronic for ~$200M), and now CEO of Salvia BioElectronics. Hubert shares how a career that started with double-layer DVD technology at Philips led him to building a patient-centred neuromodulation implant for treatment-resistant migraine and what 25 years of hard-won startup experience has taught him about doing it right.</p><p><br></p><p>Key Topics</p><p>From Philips R&amp;D to Medtronic acquisition: Hubert&#39;s path into neuromodulation</p><p>Why chronic migraine is a neurological disorder, not just a headache</p><p>The MySalvia system: how a battery-free implant targets treatment-resistant migraine</p><p>FDA Breakthrough Device Designation: what it means in practice</p><p>Why reimbursement strategy must start before you design the product</p><p>Building patient-centricity into company culture from day one</p><p>The emotional reality of being a medtech founder and who to call when it gets hard</p><p><br></p><p>Related Insights</p><p>The clinical case for neuromodulation in migraine: decades of physician-led experimentation</p><p>Positioning for payers: building economic and clinical evidence in parallel with regulatory approval</p><p>How patient advocacy drives market adoption for novel implantable therapies</p><p>The 14–17 year medtech funding gap and why consistent de-risking milestones matter more than ever</p><p><br></p><p>Core Challenges</p><p>Treatment-resistant migraine patients, those who have failed CGRP inhibitors and Botox, have no meaningful therapeutic option. The disease progressively worsens, and its invisibility compounds the psychological burden: isolation, shame, and the constant fear of the next attack.</p><p>Bringing a novel implantable neuromodulation system to market requires simultaneous mastery of regulatory strategy, reimbursement landscape, and clinical evidence design, areas most early-stage founders engage too late, at significant cost.</p><p><br></p><p>Tune in now to hear how Hubert Martens is building the therapy that treatment-resistant migraine patients have been waiting for and the hard lessons from three decades in neuromodulation that shaped how he&#39;s doing it.</p><p><br></p><p>The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. </p><p><br></p><p>To learn more about Cruxx,<a href="https://www.thisiscruxx.com/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a></p><p><br></p><p>A big thank you to our sponsors on this season of the podcast; </p><p><br></p><p><a href="https://www.linkedin.com/company/the-technology-partnership/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a> With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you&#39;re a startup or a multinational, <a href="https://www.linkedin.com/company/the-technology-partnership/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a> can accelerate your development with the latest technologies. Learn more at <a href="http://ttp.com/">⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠</a></p><p><br></p><p><br></p><p><br></p><p><br></p>